New biologic: Soliris.
- Published in:
- Formulary, 2007, v. 42, n. 4, p. 215
- Publication type:
- Article
Works matching DE "ALEXION Pharmaceuticals Inc."
Results: 10
1
2
Does the patent office really believe delay occurs before it actually occurs? The effect of Wyeth et al v. Dudas on patent term adjustments.
- Published in:
- Journal of Generic Medicines, 2009, v. 6, n. 3, p. 272, doi. 10.1057/jgm.2009.6
- By:
- Publication type:
- Article
3
Phase III.
- Published in:
- Applied Clinical Trials, 2005, v. 14, n. 10, p. 18
- Publication type:
- Article
4
Around the world in a month.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 7, p. 683, doi. 10.1038/nbt0715-683b
- Publication type:
- Article
5
Alexion pays big for Synageva's rare disease drug candidate.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 7, p. 679, doi. 10.1038/nbt0715-679
- By:
- Publication type:
- Article
6
Public biotech 2013-the numbers.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 7, p. 626, doi. 10.1038/nbt.2949
- By:
- Publication type:
- Article
7
Rarefied drug pricing.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 5, p. 398, doi. 10.1038/nbt.2912
- Publication type:
- Article
8
The rarest of bounties.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 8, p. 696, doi. 10.1038/nbt.2649
- By:
- Publication type:
- Article
9
E. coli crisis opens door for Alexion drug trial.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 8, p. 671, doi. 10.1038/nbt0811-671
- By:
- Publication type:
- Article
10
Complement inhibitors finally find orphan niches.
- Published in:
- Nature Biotechnology, 2006, v. 24, n. 4, p. 371, doi. 10.1038/nbt0406-371
- By:
- Publication type:
- Article